Calithera Biosciences has commenced a Phase I/II clinical trial of its telaglenastat (CB-839) in combination with Pfizer’s palbociclib (Ibrance) for the treatment of cancer.
Telaglenastat is a glutaminase inhibitor, while palbociclib inhibits cyclin-dependent kinase (CDK) 4/6.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Genetic alterations, including KRAS mutations, are known to lead to increased glutamine metabolism in cancer cells.
Preclinical studies in KRAS-mutated cancer models demonstrated that telaglenastat has synergistic anti-tumour effects when combined with CDK4/6 inhibitors. This synergistic approach was observed to boost cell cycle arrest and block cancer cell proliferation.
The open-label Phase I/II trial will assess the safety and anti-tumour activity of the combination in locally advanced/metastatic KRAS-mutated colorectal cancer (CRC) patients.
The study will also involve participants with KRAS-mutated non-small cell lung cancer (NSCLC). Patients who are refractory or intolerant to standard therapies will be enrolled.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe first subject in the trial has already been treated with a combination of telaglenastat and palbociclib.
